Velkommen til Advice Capital

Velkommen til Advice Capital

Vi er glade for at byde Advice Capital A/S velkommen som Fundmanager på InRater fra 1. september 2016. Advice Capital A/S vil præsentere aktierne i deres investeringsforening som primært er globale valueaktier og lavt prisfastsatte vækstselskaber af høj kvalitet. Deres mål er at opnå det bedst mulige risikojusterede afkast med en betaværdi under 1, dvs. med lavere risiko end markedet …

Read more.

Daratumumab Revolutionizing How Myeloma Is Treated
---

Newsflow - MEI Pharma

Investeringen i MEI Pharma er langsigtet - også selvom den kortsigtet steg næsten 40% på Helsinn aftalen i august. Vi har derfor lavet en timeline i samarbejdet med MEI Pharma sådan at man som investor kan danne sig et indtryk af hvad der kommer til at ske henover årene. 1. August MEI Pharma modtager BTD fra FDA til Pracinostat8. August MEI Pharma …

Read more.

---
Vores investeringsforening i Advice

Vores investeringsforening i Advice

Kære investor og potentielle kunder, Vi vil hermed indbyde alle til at deltage i vores investeringsforening: Investin Advice Capital Globale (ISIN-koden DK0060696656, kortnavn INIACG), som er kommet rigtigt godt fra start (start 21. marts 2016) med et afkast på 3,9 % på 4½ måned med en lav risiko. Forvalterne har naturligvis placeret egne midler i foreningen i det omfang de ikke er …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.